Pressmeddelanden från Gubra

Gubra announces positive GUBamy Phase 1 SAD data (correction)

The correction in this announcement refers solely that that company announcement published today at 5.

MFN • 13 Nov 18:36

Gubra announces positive GUBamy Phase 1 SAD data

MFN • 13 Nov 17:41

Trading statement Q3-2024: Another strong quarter

Today, Gubra releases its results for the third quarter of 2024.

MFN • 07 Nov 07:30

Gubra announces discontinuation of development of NYP2 in obesity with Boehringer Ingelheim

Today Gubra announces that Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2...

MFN • 31 Oct 11:07

Major shareholder announcement

MFN • 06 Sep 21:42

Interim report H1 2024: Strong performance across Gubra

Today, Gubra released its interim report for the first half of 2024.

MFN • 22 Aug 07:30

Gubra raises financial outlook for 2024

Today, Gubra announces an upgrade to its full-year 2024 financial outlook.

MFN • 21 Aug 17:12

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' sha...

MFN • 10 Jul 23:38

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no.

MFN • 02 Jul 20:25

Boehringer Ingelheim and Gubra announce start of clinical development of a potential first-in-class, triple agonist, obesity treatment

Hørsholm, Denmark and Ingelheim, Germany, 1 July, 2024 | Boehringer Ingelheim and Gubra today announced the launch of the Phase 1 study (NCT...

MFN • 01 Jul 07:30

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' sha...

MFN • 28 Jun 12:05

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no.

MFN • 04 Jun 15:30

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no.

MFN • 04 Jun 15:25

Trading statement Q1-2024: Strong start to the year

Today, Gubra releases its results for the first quarter of 2024.

MFN • 07 May 07:30

Gubra raises financial outlook for 2024

Today, Gubra announces an upgrade to its full-year 2024 financial outlook.

MFN • 06 May 17:15

Gubra unveils UCN2 as novel anti-obesity drug candidate for healthy weight loss

Gubra announces the selection of a development candidate and unveils urocortin-2 (UCN2) as a novel anti-obesity drug candidate for healthy w...

MFN • 17 Apr 07:30

RESOLUTIONS OF GUBRA A/S' ANNUAL GENERAL MEETING 2024

MFN • 04 Apr 12:32

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' sha...

MFN • 03 Apr 21:45

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' sha...

MFN • 03 Apr 21:35

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' sha...

MFN • 27 Mar 14:45

Major shareholder announcement: The Capital Group Companies Inc.

MFN • 26 Mar 22:45

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' sha...

MFN • 25 Mar 11:29

Major shareholder announcement

MFN • 25 Mar 09:56

NOTICE TO CONVENE ANNUAL GENERAL MEETING 2024

MFN • 06 Mar 09:00

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' sha...

MFN • 04 Mar 21:41

Annual Report 2023 – Revenue in the CRO business growing by 29% to record high level

In 2023, organic revenue growth in the CRO business was 29% compared to latest guidance of 25-28%, while adjusted EBIT-margin amounted to 27...

MFN • 28 Feb 07:30

Gubra concludes the research agreement with UK Biotech

Today, Gubra announces the finalization of its two-year explorative research agreement with Silence Therapeutics PLC that was signed in earl...

MFN • 26 Jan 13:33

Gubra and Boehringer Ingelheim sign 4th partnership, expanding their successful obesity treatment discovery collaboration

Today, Gubra announces the signing of a new research and license agreement with Boehringer Ingelheim to discover novel peptides for the trea...

MFN • 13 Dec 2023 17:19

Gubra announces first subject dosed in Phase 1 clinical trial of amylin agonist (GUBamy) for the treatment of obesity

Today, Gubra announces that the first human subject has been dosed with a new long-acting amylin agonist (GUBamy) as a potential treatment f...

MFN • 29 Nov 2023 12:51

Trading statement Q3-2023: Continued strong performance

Today, Gubra released its trading statement for the third quarter of 2023.

MFN • 08 Nov 2023 07:30

Gubra strengthens Board of Directors

Gubra, a leader in preclinical services within metabolic and fibrotic diseases and with a strong pipeline of novel discovery projects, today...

MFN • 01 Nov 2023 11:01

Gubra - Extraordinary general meeting

MFN • 01 Nov 2023 10:40

Gubra enters into a Market Maker Agreement

MFN • 26 Oct 2023 12:35

Gubra raises financial guidance for full-year 2023

Today, Gubra announces preliminary Q3 and 9M 2023 results for the CRO business and revises its revenue and EBIT outlook for 2023 upwards, dr...

MFN • 26 Oct 2023 08:01

Gubra opens its first US office in Boston

Gubra announces that it is opening its first US office on Kendall Square in Boston, the epicenter for the pharma and biotech community on th...

MFN • 24 Oct 2023 07:30

NOTICE TO CONVENE EXTRAORDINARY GENERAL MEETING

MFN • 09 Oct 2023 14:00

Gubra submits clinical trial application (CTA) for first-in-human amylin trial

Gubra announces that a clinical trial application (CTA) for the anti-obesity amylin project has been submitted to the Medicines and Healthca...

MFN • 06 Sep 2023 09:58

Completion of share buy-back programme

MFN • 01 Sep 2023 11:41

Gubra resumes its share buy-back programme to hedge incentive scheme obligations

Gubra A/S (“Gubra” or the “Company”) today announces the resumption of its share buy-back programme, pursuant to which the Company intends t...

MFN • 28 Aug 2023 08:15

Interim report H1-2023: Strong performance and ahead of expectations

Today, Gubra released its interim report for the first half of 2023.

MFN • 25 Aug 2023 07:30

Gubra announces termination of collaboration with Bayer

MFN • 23 Aug 2023 16:44

Gubra A/S announces signing of collaboration agreement with Hemab ApS

Today, Gubra announces the signing of an agreement with Hemab concerning a peptide collaboration.

MFN • 21 Aug 2023 15:29

Gubra raises financial guidance for full-year 2023

Today, Gubra announces preliminary Q2 and H1 2023 revenue figures for the CRO business and revises its revenue outlook for 2023 upwards, dri...

MFN • 15 Aug 2023 13:19

Information on share buy-back programme

MFN • 28 Jul 2023 19:41

Gubra launches share buy-back programme to hedge incentive scheme obligations

Gubra A/S (“Gubra” or the “Company”) today announces the initiation of a share buy-back programme, pursuant to which the Company intends to ...

MFN • 30 Jun 2023 08:00

Gubra acquires research service provider MiniGut ApS

Today, Gubra announces the acquisition of the Danish minipig service provider MiniGut ApS.

MFN • 29 Jun 2023 07:00

Börskollen

För dig med koll på börsen

Pressmeddelanden från Gubra

Gubra announces positive GUBamy Phase 1 SAD data (correction)

Gubra announces positive GUBamy Phase 1 SAD data

Trading statement Q3-2024: Another strong quarter

Gubra announces discontinuation of development of NYP2 in obesity with Boehringer Ingelheim

Major shareholder announcement

Interim report H1 2024: Strong performance across Gubra

Gubra raises financial outlook for 2024

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Boehringer Ingelheim and Gubra announce start of clinical development of a potential first-in-class, triple agonist, obesity treatment

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Trading statement Q1-2024: Strong start to the year

Gubra raises financial outlook for 2024

Gubra unveils UCN2 as novel anti-obesity drug candidate for healthy weight loss

RESOLUTIONS OF GUBRA A/S' ANNUAL GENERAL MEETING 2024

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Major shareholder announcement: The Capital Group Companies Inc.

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Major shareholder announcement

NOTICE TO CONVENE ANNUAL GENERAL MEETING 2024

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Annual Report 2023 – Revenue in the CRO business growing by 29% to record high level

Gubra concludes the research agreement with UK Biotech

Gubra and Boehringer Ingelheim sign 4th partnership, expanding their successful obesity treatment discovery collaboration

Gubra announces first subject dosed in Phase 1 clinical trial of amylin agonist (GUBamy) for the treatment of obesity

Trading statement Q3-2023: Continued strong performance

Gubra strengthens Board of Directors

Gubra - Extraordinary general meeting

Gubra enters into a Market Maker Agreement

Gubra raises financial guidance for full-year 2023

Gubra opens its first US office in Boston

NOTICE TO CONVENE EXTRAORDINARY GENERAL MEETING

Gubra submits clinical trial application (CTA) for first-in-human amylin trial

Completion of share buy-back programme

Gubra resumes its share buy-back programme to hedge incentive scheme obligations

Interim report H1-2023: Strong performance and ahead of expectations

Gubra announces termination of collaboration with Bayer

Gubra A/S announces signing of collaboration agreement with Hemab ApS

Gubra raises financial guidance for full-year 2023

Information on share buy-back programme

Gubra launches share buy-back programme to hedge incentive scheme obligations

Gubra acquires research service provider MiniGut ApS